The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells
- Laboratory of Molecular Oncology, Department of Urology, Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585 (Japan)
- Department of Human Pathology (Second Department of Pathology), Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585 (Japan)
Highlights: Black-Right-Pointing-Pointer EZH2 is overexpressed in the nuclei of renal cancer cells. Black-Right-Pointing-Pointer Nuclear EZH2 is associated with advanced stage and worse survival of RCC patients. Black-Right-Pointing-Pointer EZH2 is negatively regulated by miR-101 in renal cancer cells. Black-Right-Pointing-Pointer Depletion of EZH2 leads to re-expression of p27Kip1. Black-Right-Pointing-Pointer Reintroduction of miR-101 results in suppression of cell proliferation. -- Abstract: We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.
- OSTI ID:
- 22207888
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 422, Issue 4; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis
Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma